Changing the Future of Healthcare with the Early Detection of Cancer
Abcodia is a specialist company engaged in the discovery and verification of biomarkers for cancer screening. Our mission is to change the way that biomarkers are developed to allow the earlier diagnosis of cancer and in this way help people live longer and healthier lives.
For more information about biomarkers for the early detection of cancer and Abcodia's capability and expertise please download our presentation.
A unique serum bank
In 2001, the UKCTOCS trial began collecting serum samples from over 200,000 women volunteers; this serum bank now contains over 500,000 serum samples, including over 350,000 longitudinal samples. In addition to the serum, there is a comprehensive database of phenotypic, demographic and disease incidence for each volunteer. Abcodia works in close partnership with the Gynaecological Cancer Research Centre at UCL. Click here for more information about the GCRC.
Click here for more information about how the serum biobank was created and the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Get in touch
To find out more about what Abcodia can offer and collaboration opportunities,
please contact us
Early Diagnosis Consortium (EDC)
Abcodia has formed a strategic alliance with Cancer Research UK and Cancer Research Technology (CRT). The aim of EDC to discover and validate cancer biomarkers with the utility for their eventual use in cancer screening. We are now seeking technology partners who have best in class technology for biomarker discovery. Please contact us or visit the EDC web pages for more information.
Abcodia's Cancer Initiatives
The early detection of cancer and effective screening have been shown to improve survival and reduce deaths. Abcodia has analysed the cohort of volunteers and serum samples in four key cancer areas. Click any initiative below for more details.
Dr Julie Barnes wins the 2013 WISE Award for Enterprise & Innovation
The 2013 prestigious WISE award for Enterprise and Innovation has been awarded to Dr Julie Barnes, CEO of Abcodia. It was presented by HRH The Princess Royal during a ceremony at the Science Museum in London on 14th November 2013. More
Abcodia Licenses the Risk of Ovarian Cancer Algorithm (ROCA®)
Abcodia has announced that it has been granted a world-wide exclusive license to ROCA from the Massachusetts General Hospital and Queen Mary, University of London. ROCA is a diagnostic test aimed at the screening and early detection of ovarian cancer and is the subject of several ongoing clinical trials. Abcodia are in active discussions with a potential partners in different territories and are exploring ways in which ROCA can be used in clinical practice. More